{
  "05Y.DE": {
    "city": "Halle",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Vivoryon Therapeutics N.V.",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VIVORYON THERAPEUTICS",
    "state": null,
    "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
    "website": "http://www.vivoryon.com",
    "zipcode": "06120"
  },
  "05Y.F": {
    "city": "Halle",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Vivoryon Therapeutics N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VIVORYON THERAPEUTICS",
    "state": null,
    "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
    "website": "http://www.vivoryon.com",
    "zipcode": "06120"
  },
  "0N6.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "NOXXON Pharma N.V.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NOXXON PH.CONF.IPO EO-,01",
    "state": null,
    "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
    "website": "http://www.noxxon.com",
    "zipcode": "10589"
  },
  "1846.HK": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Medical Care Facilities",
    "long_name": "EuroEyes International Eye Clinic Limited",
    "market": "hk_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "EUROEYES",
    "state": null,
    "summary": "EuroEyes International Eye Clinic Limited provides vision correction services in Germany, Denmark, and the People's Republic of China. The company offers refractive laser surgery, which include ReLEx SMILE and FemtoLASIK; phakic lens (ICL) surgery; lens exchange surgery comprising the monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. Its correction services are used for the treatment of myopia, high myopia, presbyopia, and cataract surgeries. The company serves mid-to-high income level customers, who primarily seek surgery to treat their myopia; and above 45 years of age, who primarily seek surgery to treat their presbyopia or cataract. It operates consultation centers and clinics for eye treatment and LASIK centers; and sells pharmaceutical products. The company is also involved in eye clinic equipment and lenses trading; and ophthalmic equipment renting and spaces operating activities. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.euroeyes.hk",
    "zipcode": "20355"
  },
  "22UA.F": {
    "city": "Mainz",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioNTech SE",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIONTECH SE SPON. ADRS 1",
    "state": null,
    "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.",
    "website": "http://www.biontech.de",
    "zipcode": "55131"
  },
  "39K.F": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CENTOGENE N.V. EO -,12",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "39K.MU": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CENTOGENE N.V. EO -,12",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "5CV.DE": {
    "city": "TÃ¼bingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "CureVac N.V.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CUREVAC N.V.  O.N.",
    "state": null,
    "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company is also developing RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.",
    "website": "http://www.curevac.com",
    "zipcode": "72076"
  },
  "5CV.F": {
    "city": "TÃ¼bingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CureVac N.V.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CUREVAC N.V.  O.N.",
    "state": null,
    "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company is also developing RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.",
    "website": "http://www.curevac.com",
    "zipcode": "72076"
  },
  "A28.F": {
    "city": "Heidelberg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Affimed N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AFFIMED N.V.  EO-,01",
    "state": null,
    "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
    "website": "http://www.affimed.com",
    "zipcode": "69120"
  },
  "AAQ1.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "aap Implantate AG",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AAP IMPLANTATE AG O.N.",
    "state": null,
    "summary": "aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.",
    "website": "http://www.aap.de",
    "zipcode": "12099"
  },
  "AAQ1.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "aap Implantate AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AAP IMPLANTATE AG O.N.",
    "state": null,
    "summary": "aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.",
    "website": "http://www.aap.de",
    "zipcode": "12099"
  },
  "AFMD": {
    "city": "Heidelberg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Affimed N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Affimed N.V.",
    "state": null,
    "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
    "website": "http://www.affimed.com",
    "zipcode": "69120"
  },
  "AFX.DE": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC AG",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "AFX.F": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC AG",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "AFX.VI": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC AG",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "AFXA.F": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC ADR 1",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "AJ91.DE": {
    "city": "Cologne",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "DocCheck AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DOCCHECK AG NA O.N.",
    "state": null,
    "summary": "DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.",
    "website": "http://www.doccheck.ag",
    "zipcode": "50823"
  },
  "AJ91.F": {
    "city": "Cologne",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "DocCheck AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DOCCHECK AG NA O.N.",
    "state": null,
    "summary": "DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.",
    "website": "http://www.doccheck.ag",
    "zipcode": "50823"
  },
  "ALDNF": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Aladdin Healthcare Technologies SE",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALADDIN HEALTHCARE TECHNOLOGIES",
    "state": null,
    "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
    "website": "http://www.aladdinid.com",
    "zipcode": "10117"
  },
  "ALNOX.PA": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "NOXXON Pharma N.V.",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NOXXON",
    "state": null,
    "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
    "website": "http://www.noxxon.com",
    "zipcode": "10589"
  },
  "B8F.DE": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Biofrontera AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOFRONTERA AG NA O.N.",
    "state": null,
    "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
    "website": null,
    "zipcode": "51377"
  },
  "B8F.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biofrontera AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOFRONTERA AG NA O.N.",
    "state": null,
    "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
    "website": null,
    "zipcode": "51377"
  },
  "B8FE.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biofrontera AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOFRONTERA AG SP.ADR/2",
    "state": null,
    "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
    "website": null,
    "zipcode": "51377"
  },
  "B8FE.SG": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Biofrontera AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Biofrontera AG (Spons.ADRs)/2 o",
    "state": null,
    "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
    "website": null,
    "zipcode": "51377"
  },
  "BAY.MI": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYA.DE": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Major",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER ADR /1/4",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYA.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER ADR /1/4",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.DE": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG NA O.N.",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG NA O.N.",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.VI": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYNN.MX": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - Major",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYRY": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYZF": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BFRA": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Biofrontera AG",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Biofrontera AG American Deposit",
    "state": null,
    "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
    "website": null,
    "zipcode": "51377"
  },
  "BIO.DE": {
    "city": "Dreieich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Biotest Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTEST AG ST O.N.",
    "state": null,
    "summary": "Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.",
    "website": "http://www.biotest.com",
    "zipcode": "63303"
  },
  "BIO.F": {
    "city": "Dreieich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biotest Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTEST AG ST O.N.",
    "state": null,
    "summary": "Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.",
    "website": "http://www.biotest.com",
    "zipcode": "63303"
  },
  "BIO3.DE": {
    "city": "Dreieich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Biotest Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTEST AG VZ O.N.",
    "state": null,
    "summary": "Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.",
    "website": "http://www.biotest.com",
    "zipcode": "63303"
  },
  "BIO3.F": {
    "city": "Dreieich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biotest Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTEST AG VZ O.N.",
    "state": null,
    "summary": "Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.",
    "website": "http://www.biotest.com",
    "zipcode": "63303"
  },
  "BIO3.VI": {
    "city": "Dreieich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "Biotest Aktiengesellschaft",
    "market": "at_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTEST AG VZ",
    "state": null,
    "summary": "Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.",
    "website": "http://www.biotest.com",
    "zipcode": "63303"
  },
  "BNN.DE": {
    "city": "Zwingenberg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "BRAIN Biotech AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BRAIN BIOTEC  NA O.N.",
    "state": null,
    "summary": "BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.",
    "website": "http://www.brain-biotech.de",
    "zipcode": "64673"
  },
  "BNN.F": {
    "city": "Zwingenberg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BRAIN Biotech AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BRAIN BIOTEC  NA O.N.",
    "state": null,
    "summary": "BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.",
    "website": "http://www.brain-biotech.de",
    "zipcode": "64673"
  },
  "BNTX": {
    "city": "Mainz",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "BioNTech SE",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BioNTech SE",
    "state": null,
    "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.",
    "website": "http://www.biontech.de",
    "zipcode": "55131"
  },
  "BNTX.VI": {
    "city": "Mainz",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "BioNTech SE",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIONTECH SE ADR",
    "state": null,
    "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.",
    "website": "http://www.biontech.de",
    "zipcode": "55131"
  },
  "CAKFY": {
    "city": "Stuttgart",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Distribution",
    "long_name": "McKesson Europe AG",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MCKESSON EUROPE AG",
    "state": null,
    "summary": "McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division operates approximately 2,300 own and 300 managed retail pharmacies and approximately 7,000 participants in its brand partnership schemes. The Pharmacy Solutions division engages in the wholesale of pharmaceutical products. It also provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs in the United Kingdom, Germany, France, Portugal, and Belgium. This division serves its customers through 118 wholesale branches that supply approximately 100,000 pharmaceutical products to approximately 50,000 pharmacies and hospitals. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG operates as a subsidiary of McKesson Corporation.",
    "website": "http://www.mckesson.eu/mck-en",
    "zipcode": "70137"
  },
  "CDZ.MU": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Health Information Services",
    "long_name": "Lifespot Capital AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFESPOT CAPITAL AG O.N.",
    "state": null,
    "summary": "Lifespot Capital AG offers telemedical and medical big data solutions to e-health market participants and stakeholders. Lifespot Capital AG was formerly known as NBIC Capital AG and changed its name to Lifespot Capital AG in May, 2015. The company was founded in 2005 and is based in Munich, Germany.",
    "website": "http://www.lifespotcapital.com",
    "zipcode": "80335"
  },
  "CLS1.HM": {
    "city": "Stuttgart",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "HAM",
    "industry": "Medical Distribution",
    "long_name": "McKesson Europe AG",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MCKESSON EUROPE  NA O.N.",
    "state": null,
    "summary": "McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division operates approximately 2,300 own and 300 managed retail pharmacies and approximately 7,000 participants in its brand partnership schemes. The Pharmacy Solutions division engages in the wholesale of pharmaceutical products. It also provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs in the United Kingdom, Germany, France, Portugal, and Belgium. This division serves its customers through 118 wholesale branches that supply approximately 100,000 pharmaceutical products to approximately 50,000 pharmacies and hospitals. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG operates as a subsidiary of McKesson Corporation.",
    "website": "http://www.mckesson.eu/mck-en",
    "zipcode": "70137"
  },
  "CNTG": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Centogene N.V.",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "CNWK.DE": {
    "city": "Teltow",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "co.don AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CO.DON AG  INH. O.N.",
    "state": null,
    "summary": "co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
    "website": "http://www.codon.de",
    "zipcode": "14513"
  },
  "CNWK.F": {
    "city": "Teltow",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "co.don AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CO.DON AG  INH. O.N.",
    "state": null,
    "summary": "co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
    "website": "http://www.codon.de",
    "zipcode": "14513"
  },
  "COP.DE": {
    "city": "Koblenz",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "CompuGroup Medical SE & Co. KGaA",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "COMPUGROUP MED. NA O.N.",
    "state": null,
    "summary": "CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for registered physicians, medical care centers, and physicians networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides administrative and billing-related software applications for pharmacies. Its software solution provides information and decision support to manage various aspects of supply chain for medication. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals, rehabilitation centers, social services, multi-location hospital networks and regional care organizations, and medical laboratories. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases for healthcare service providers, as well as digital healthcare stock, consumer portals, and mobile apps. This segment also offers security solutions for healthcare providers. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to CompuGroup Medical SE & Co. KGaA in June 2020. CompuGroup Medical SE & Co. KGaA was founded in 1987 and is headquartered in Koblenz, Germany.",
    "website": "http://www.cgm.com",
    "zipcode": "56070"
  },
  "CVAC": {
    "city": "TÃ¼bingen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "CureVac N.V.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CureVac N.V.",
    "state": null,
    "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.",
    "website": "http://www.curevac.com",
    "zipcode": "72076"
  },
  "CVAC.VI": {
    "city": "TÃ¼bingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "CureVac N.V.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CUREVAC NV",
    "state": null,
    "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company is also developing RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.",
    "website": "http://www.curevac.com",
    "zipcode": "72076"
  },
  "CZMWF": {
    "city": "Jena",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC AG",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "CZMWY": {
    "city": "Jena",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Carl Zeiss Meditec AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CARL ZEISS MEDITEC AG",
    "state": null,
    "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
    "website": "http://www.zeiss.de/meditec-ag/home.html",
    "zipcode": "07745"
  },
  "DBI.DU": {
    "city": "Hennigsdorf",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "DUS",
    "industry": "Biotechnology",
    "long_name": "Deutsche Biotech Innovativ AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DT.BIOTECH INNOV.AG  O.N.",
    "state": null,
    "summary": "Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, a monoclonal adrenomedullin-specific antibody, which is in Phase II clinical trial as a therapy against septic shock to reduce sepsis mortality. It also develops various drugs for the prevention of breast cancer and tumor. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG is based in Hennigsdorf, Germany.",
    "website": "http://www.dbi-ag.de",
    "zipcode": "16761"
  },
  "DBI.F": {
    "city": "Hennigsdorf",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Deutsche Biotech Innovativ AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DT.BIOTECH INNOV.AG  O.N.",
    "state": null,
    "summary": "Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, a monoclonal adrenomedullin-specific antibody, which is in Phase II clinical trial as a therapy against septic shock to reduce sepsis mortality. It also develops various drugs for the prevention of breast cancer and tumor. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG is based in Hennigsdorf, Germany.",
    "website": "http://www.dbi-ag.de",
    "zipcode": "16761"
  },
  "DGWPF": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK AG & CO KGAA",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DMP.DE": {
    "city": "GrÃ¼nwald",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Dermapharm Holding SE",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "DERMAPHARM HLDG INH O.N.",
    "state": null,
    "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
    "website": "http://www.dermapharm.de",
    "zipcode": "82031"
  },
  "DMP.F": {
    "city": "GrÃ¼nwald",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Dermapharm Holding SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "DERMAPHARM HLDG INH O.N.",
    "state": null,
    "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
    "website": "http://www.dermapharm.de",
    "zipcode": "82031"
  },
  "DRW1.F": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK GEN.S.D",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DRW3.DE": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK VZO O.N.",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DRW3.F": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK VZO O.N.",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DRW3.VI": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "at_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK AG VZ",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DRW8.DE": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK ST.A.O.N.",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "DRW8.F": {
    "city": "LÃ¼beck",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Drägerwerk AG & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DRAEGERWERK ST.A.O.N.",
    "state": null,
    "summary": "DrÃ¤gerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving equipment and systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems. DrÃ¤gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in LÃ¼beck, Germany.",
    "website": "http://www.draeger.com",
    "zipcode": "23558"
  },
  "E8X.DE": {
    "city": "Singen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "elexxion AG",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELEXXION AG",
    "state": null,
    "summary": "elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany. It offers dental diode lasers under the elexxion pico, elexxion nano, and elexxion claros names; and elexxion pico lite, a soft laser therapy. The company also provides Odobleach; and perio green, a therapy product for the photothermal therapy of periodontology and periimplantitis, as well as offers repair services. The company was founded in 2002 and is based in Singen, Germany. elexxion AG is a subsidiary of Tian Ying Medical Instrument Co., Ltd.",
    "website": "http://www.elexxion.com",
    "zipcode": "78224"
  },
  "E8X.F": {
    "city": "Singen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "elexxion AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELEXXION AG",
    "state": null,
    "summary": "elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany. It offers dental diode lasers under the elexxion pico, elexxion nano, and elexxion claros names; and elexxion pico lite, a soft laser therapy. The company also provides Odobleach; and perio green, a therapy product for the photothermal therapy of periodontology and periimplantitis, as well as offers repair services. The company was founded in 2002 and is based in Singen, Germany. elexxion AG is a subsidiary of Tian Ying Medical Instrument Co., Ltd.",
    "website": "http://www.elexxion.com",
    "zipcode": "78224"
  },
  "ECX.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG NA O.N.",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "ECX.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG NA O.N.",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "EIF.F": {
    "city": "Bonn",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Eifelhöhen-Klinik AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EIFELHOEHEN-KLINIK O.N.",
    "state": null,
    "summary": "EifelhÃ¶hen-Klinik AG operates facilities for outpatient and inpatient rehabilitation, elderly care, and outpatient medical care in Germany. It operates clinics that provide rehabilitation services in the areas of geriatrics, internal medicine, orthopedics, neurology, cardiology, and neurosurgery, as well as stroke diseases. The company also operates a care facility with 39 beds and a medical care center. EifelhÃ¶hen-Klinik AG was founded in 1970 and is headquartered in Bonn, Germany.",
    "website": "http://eifelhoehen-klinik.ag",
    "zipcode": "53117"
  },
  "EPGNF": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "EPGNY": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "EUZ.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "Eckert & Ziegler Strahlen- und Medizintechnik AG",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ECKERT+ZIEGLER AG O.N.",
    "state": null,
    "summary": "Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment's products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.",
    "website": "http://www.ezag.com",
    "zipcode": "13125"
  },
  "EUZ.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Eckert & Ziegler Strahlen- und Medizintechnik AG",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ECKERT+ZIEGLER AG O.N.",
    "state": null,
    "summary": "Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment's products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.",
    "website": "http://www.ezag.com",
    "zipcode": "13125"
  },
  "EVOTF": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.DE": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE  INH O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE  INH O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.VI": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "at_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVTA.DE": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drugs - Generic",
    "long_name": "Evotec SE",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE ADR/2 O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVTA.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE ADR/2 O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVTCY": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "FMCQF": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS MEDICAL CARE AG & CO ",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FME.DE": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESEN.MED.CARE KGAA O.N.",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FME.F": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESEN.MED.CARE KGAA O.N.",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FME.MI": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS MEDICAL CARE",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FME.VI": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESEN.MED.CARE KGAA",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FMEA.F": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS MD.CARE ADR 1/2",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FMEN.MX": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Hospitals",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS MEDICAL CARE AG & CO ",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FMS": {
    "city": "Bad Homburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius Medical Care AG & Co. KGaA",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Fresenius Medical Care AG",
    "state": null,
    "summary": "Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
    "website": "http://www.freseniusmedicalcare.com",
    "zipcode": "61352"
  },
  "FRE.DE": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE+CO.KGAA O.N.",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FRE.F": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE+CO.KGAA O.N.",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FRE.MI": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FRE.VI": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE+CO.KGAA",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FREA.F": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE+CO. ADR 1/4",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FREN.MX": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE&CO KGAA",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FSNUF": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE&CO KGAA",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FSNUY": {
    "city": "Bad Homburg vor der HÃ¶he",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Fresenius SE & Co. KGaA",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "FRESENIUS SE&CO KGAA",
    "state": null,
    "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.",
    "website": "http://www.fresenius.com",
    "zipcode": "61352"
  },
  "FYB.DE": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Formycon AG",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FORMYCON AG",
    "state": null,
    "summary": "Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
    "website": "http://www.formycon.com",
    "zipcode": "82152"
  },
  "FYB.F": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Formycon AG",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FORMYCON AG",
    "state": null,
    "summary": "Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
    "website": "http://www.formycon.com",
    "zipcode": "82152"
  },
  "GME.DE": {
    "city": "Geschwenda",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "Geratherm Medical AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GERATHERM O.N.",
    "state": null,
    "summary": "Geratherm Medical AG operates as a medical technology company in Germany. The company operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment primarily offers clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infection, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products under the Spirostik and Spirostik Complete names, principally for the pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment provides warming systems under the UniqueTemp and Unique Resc+ brand names to maintain body temperature during operations and in rescue situations; and nomag IC, an incubator system for use in magnetic resonance imaging of premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation used in preventing strokes. It markets its products through pharmacies, hospitals, and clinics. The company exports its products to Europe, South America, the Middle East, Asia, Africa, the United States, and internationally. Geratherm Medical AG is headquartered in Geschwenda, Germany.",
    "website": "http://www.geratherm.com",
    "zipcode": "99331"
  },
  "GME.F": {
    "city": "Geschwenda",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Geratherm Medical AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GERATHERM O.N.",
    "state": null,
    "summary": "Geratherm Medical AG operates as a medical technology company in Germany. The company operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment primarily offers clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infection, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products under the Spirostik and Spirostik Complete names, principally for the pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment provides warming systems under the UniqueTemp and Unique Resc+ brand names to maintain body temperature during operations and in rescue situations; and nomag IC, an incubator system for use in magnetic resonance imaging of premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation used in preventing strokes. It markets its products through pharmacies, hospitals, and clinics. The company exports its products to Europe, South America, the Middle East, Asia, Africa, the United States, and internationally. Geratherm Medical AG is headquartered in Geschwenda, Germany.",
    "website": "http://www.geratherm.com",
    "zipcode": "99331"
  },
  "GXI.DE": {
    "city": "DÃ¼sseldorf",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Gerresheimer AG",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GERRESHEIMER AG",
    "state": null,
    "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass, plastic products, and drug delivery-devices and solutions primarily worldwide. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables, and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for heart failure or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in DÃ¼sseldorf, Germany.",
    "website": "http://www.gerresheimer.com",
    "zipcode": "40468"
  },
  "GXI.F": {
    "city": "DÃ¼sseldorf",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Gerresheimer AG",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GERRESHEIMER AG",
    "state": null,
    "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass, plastic products, and drug delivery-devices and solutions primarily worldwide. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables, and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for heart failure or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in DÃ¼sseldorf, Germany.",
    "website": "http://www.gerresheimer.com",
    "zipcode": "40468"
  },
  "GXI.VI": {
    "city": "DÃ¼sseldorf",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Gerresheimer AG",
    "market": "at_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GERRESHEIMER AG",
    "state": null,
    "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass, plastic products, and drug delivery-devices and solutions primarily worldwide. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables, and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for heart failure or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in DÃ¼sseldorf, Germany.",
    "website": "http://www.gerresheimer.com",
    "zipcode": "40468"
  },
  "H9O1.F": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "HumanOptics AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HUMANOPTICS AG  O.N.",
    "state": null,
    "summary": "HumanOptics AG develops, manufactures, and sells intraocular implantable solutions. The company offers artificial intraocular lenses. It also provides CUSTOMFLEX ARTIFICIALIRIS, an iris prosthesis, which is used for the medical and aesthetic reconstruction of eyes with complete or partial aniridia; and implants and accessories. HumanOptics AG serves surgeons and patients. The company is headquartered in Erlangen, Germany. HumanOptics AG is a former subsidiary of Medipart AG.",
    "website": "http://www.humanoptics.com",
    "zipcode": "91054"
  },
  "HAEK.DE": {
    "city": "SchÃ¶nefeld",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "HAEMATO AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HAEMATO AG  INH O.N.",
    "state": null,
    "summary": "HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European import medicinal products; and manufactures and distributes its own generic medicinal products. It provides pharmaceuticals in the areas of oncology, HIV/AIDS, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic treatments. The company also develops and commercializes pharmaceutical, medicinal, and medical engineering products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors and hospitals. The company was founded in 1993 and is headquartered in SchÃ¶nefeld, Germany.",
    "website": "http://www.haemato.ag",
    "zipcode": "12529"
  },
  "HEMP.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Deutsche Cannabis AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DT.CANNABIS AG  O.N.",
    "state": null,
    "summary": "Deutsche Cannabis AG engages in the acquisition, sale, and management of investments in cannabis industry primarily in Germany. It also focuses on the investment in the renewable energy sector, such as photovoltaics and cogeneration. The company was formerly known as F.A.M.E. AG and changed its name to Deutsche Cannabis AG in December 2014. Deutsche Cannabis AG was founded in 1999 and is based in Hamburg, Germany.",
    "website": "http://www.deutschecannabis.com",
    "zipcode": "22399"
  },
  "HPHA.DE": {
    "city": "Ladenburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Heidelberg Pharma AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HEIDELBERG PHARMA AG O.N.",
    "state": null,
    "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
    "website": "http://heidelberg-pharma.com",
    "zipcode": "68526"
  },
  "HPHA.F": {
    "city": "Ladenburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Heidelberg Pharma AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HEIDELBERG PHARMA AG O.N.",
    "state": null,
    "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
    "website": "http://heidelberg-pharma.com",
    "zipcode": "68526"
  },
  "IF0.DE": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "InflaRx N.V.",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INFLARX N.V.  EO 0,12",
    "state": null,
    "summary": "InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",
    "website": "http://www.inflarx.de",
    "zipcode": "07745"
  },
  "IF0.F": {
    "city": "Jena",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "InflaRx N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INFLARX N.V.  EO 0,12",
    "state": null,
    "summary": "InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",
    "website": "http://www.inflarx.de",
    "zipcode": "07745"
  },
  "IFRX": {
    "city": "Jena",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "InflaRx N.V.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "InflaRx N.V.",
    "state": null,
    "summary": "InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",
    "website": "http://www.inflarx.de",
    "zipcode": "07745"
  },
  "ILM1.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Distribution",
    "long_name": "Medios AG",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDIOS AG  O.N.",
    "state": null,
    "summary": "Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.",
    "website": "http://www.medios.ag",
    "zipcode": "10557"
  },
  "ILM1.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "Medios AG",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDIOS AG  O.N.",
    "state": null,
    "summary": "Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.",
    "website": "http://www.medios.ag",
    "zipcode": "10557"
  },
  "IMTX": {
    "city": "TÃ¼bingen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Immatics N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Immatics N.V.",
    "state": null,
    "summary": "Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.",
    "website": "http://www.immatics.com",
    "zipcode": "72076"
  },
  "IS8.DE": {
    "city": "Frechen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "ifa systems AG",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IFA SYSTEMS AG",
    "state": null,
    "summary": "ifa systems AG develops, distributes, and installs software solutions and components primarily targeted at ophthalmologists and eye clinics in health IT industry worldwide. It offers an Electronic Medical Record (EMR) dedicated to ophthalmology. The company EMR permits a detailed documentation and administration of the examination results and treatments, and can be implemented in specialist practices and eye centers, as well as ophthalmology departments in hospitals. It provides medical device interface system, a solution that is specialized in all data from ophthalmology and merge all data from different sources; clinical decision support system, analyses available clinical patient data to provide information about the guidelines, treatment methods, risks, etc; software connection platform, which connects and integrates different software products; and workflow management software, manages treatment processes; as well as Web-based registry solutions for treatment of cataract and refractive surgery. The company was founded in 1987 and is headquartered in Frechen, Germany. ifa systems AG is a subsidiary of Topcon Europe B.V.",
    "website": "http://www.ifasystems.de",
    "zipcode": "50226"
  },
  "IS8.F": {
    "city": "Frechen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "ifa systems AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IFA SYSTEMS AG",
    "state": null,
    "summary": "ifa systems AG develops, distributes, and installs software solutions and components primarily targeted at ophthalmologists and eye clinics in health IT industry worldwide. It offers an Electronic Medical Record (EMR) dedicated to ophthalmology. The company EMR permits a detailed documentation and administration of the examination results and treatments, and can be implemented in specialist practices and eye centers, as well as ophthalmology departments in hospitals. It provides medical device interface system, a solution that is specialized in all data from ophthalmology and merge all data from different sources; clinical decision support system, analyses available clinical patient data to provide information about the guidelines, treatment methods, risks, etc; software connection platform, which connects and integrates different software products; and workflow management software, manages treatment processes; as well as Web-based registry solutions for treatment of cataract and refractive surgery. The company was founded in 1987 and is headquartered in Frechen, Germany. ifa systems AG is a subsidiary of Topcon Europe B.V.",
    "website": "http://www.ifasystems.de",
    "zipcode": "50226"
  },
  "L3D.DE": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "L3D.DU": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "DUS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "L3D.F": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "LIK.DE": {
    "city": "Cologne",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "LIMES Schlosskliniken AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LIMES SCHLOSSKLINIK. O.N.",
    "state": null,
    "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
    "website": "http://www.limes-schlosskliniken.de",
    "zipcode": "50672"
  },
  "LIK.DU": {
    "city": "Cologne",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "DUS",
    "industry": "Medical Care Facilities",
    "long_name": "LIMES Schlosskliniken AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LIMES SCHLOSSKLINIK. O.N.",
    "state": null,
    "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
    "website": "http://www.limes-schlosskliniken.de",
    "zipcode": "50672"
  },
  "LIK.F": {
    "city": "Cologne",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "LIMES Schlosskliniken AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIMES SCHLOSSKLINIK. O.N.",
    "state": null,
    "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
    "website": "http://www.limes-schlosskliniken.de",
    "zipcode": "50672"
  },
  "M12.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "M1 Kliniken AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "M1 KLINIKEN AG  O.N.",
    "state": null,
    "summary": "M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select and M1 Aesthetics brands. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centres under the M1 Med Beauty, M1 Laser, and M1 Dental brand names. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.",
    "website": "http://www.m1-kliniken.de",
    "zipcode": "12557"
  },
  "M12.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "M1 Kliniken AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "M1 KLINIKEN AG  O.N.",
    "state": null,
    "summary": "M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select and M1 Aesthetics brands. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centres under the M1 Med Beauty, M1 Laser, and M1 Dental brand names. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.",
    "website": "http://www.m1-kliniken.de",
    "zipcode": "12557"
  },
  "M3V.DE": {
    "city": "Bremen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "MeVis Medical Solutions AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEVIS MEDICAL SOL.NA O.N.",
    "state": null,
    "summary": "MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",
    "website": "http://www.mevis.de",
    "zipcode": "28359"
  },
  "M3V.F": {
    "city": "Bremen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "MeVis Medical Solutions AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEVIS MEDICAL SOL.NA O.N.",
    "state": null,
    "summary": "MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",
    "website": "http://www.mevis.de",
    "zipcode": "28359"
  },
  "MAK.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "Maternus-Kliniken Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MATERNUS-KLI.AG O.N.",
    "state": null,
    "summary": "Maternus-Kliniken Aktiengesellschaft operates retirement and nursing homes, rehabilitation clinics, and various service companies that operate in the field of geriatric care and rehabilitation medicine. The company also provides emergency call, assisted living, rehabilitation, and follow-up treatment services, as well as domestic, inpatient, short term, and handicapped care services. It operates approximately 23 facilities in Germany. The company was founded in 1877 and is headquartered in Berlin, Germany.",
    "website": "http://www.maternus.de",
    "zipcode": "10117"
  },
  "MAK.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Maternus-Kliniken Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MATERNUS-KLI.AG O.N.",
    "state": null,
    "summary": "Maternus-Kliniken Aktiengesellschaft operates retirement and nursing homes, rehabilitation clinics, and various service companies that operate in the field of geriatric care and rehabilitation medicine. The company also provides emergency call, assisted living, rehabilitation, and follow-up treatment services, as well as domestic, inpatient, short term, and handicapped care services. It operates approximately 23 facilities in Germany. The company was founded in 1877 and is headquartered in Berlin, Germany.",
    "website": "http://www.maternus.de",
    "zipcode": "10117"
  },
  "MDG1.DE": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Medigene AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIGENE AG NA O.N.",
    "state": null,
    "summary": "Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
    "website": "http://www.medigene.com",
    "zipcode": "82152"
  },
  "MDG1.F": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Medigene AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIGENE AG NA O.N.",
    "state": null,
    "summary": "Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
    "website": "http://www.medigene.com",
    "zipcode": "82152"
  },
  "MDG1.VI": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "Medigene AG",
    "market": "at_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIGENE AG",
    "state": null,
    "summary": "Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
    "website": "http://www.medigene.com",
    "zipcode": "82152"
  },
  "MDGEF": {
    "city": "Munich",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Medigene AG",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIGENE AG",
    "state": null,
    "summary": "Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
    "website": "http://www.medigene.com",
    "zipcode": "82152"
  },
  "MDQK.HM": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "HAM",
    "industry": "Health Information Services",
    "long_name": "MediNavi AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDINAVI AG  INH. O.N.",
    "state": null,
    "summary": "MediNavi AG owns and operates a platform that allows patients to find doctors and a second doctor's opinion. The company was founded in 2008 and is based in Munich, Germany.",
    "website": "http://www.medinavi.de",
    "zipcode": "80634"
  },
  "MED.DE": {
    "city": "Offenburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "MEDICLIN Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDICLIN AG",
    "state": null,
    "summary": "MEDICLIN Aktiengesellschaft operates hospitals in Germany. It operates through Post-Acute, Acute, and Other Activities segments. It offers medical services focusing on cardiology, cardiac surgery, and cardiological rehabilitation services; acute neurological treatment and neurological early rehabilitation services; psychosomatic and psychiatry; orthopedics; geriatrics; treatment of diabetes, obesity and kidney diseases, chronic pain, and rehabilitation after cochlear implants; radiation therapy; internal medicine; and neurosurgery and neuroradiology. The company also provides services in the areas of oncology, and ENT, as well as acute outpatient services. As of January 01, 2021, it owned 35 clinics, 7 nursing care facilities, and 10 medical care centers with a total capacity of approximately 8,350 beds/ care places in 11 German federal states. The company is headquartered in Offenburg, Germany.",
    "website": "http://www.mediclin.de",
    "zipcode": "77652"
  },
  "MED.F": {
    "city": "Offenburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "MEDICLIN Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDICLIN AG",
    "state": null,
    "summary": "MEDICLIN Aktiengesellschaft operates hospitals in Germany. It operates through Post-Acute, Acute, and Other Activities segments. It offers medical services focusing on cardiology, cardiac surgery, and cardiological rehabilitation services; acute neurological treatment and neurological early rehabilitation services; psychosomatic and psychiatry; orthopedics; geriatrics; treatment of diabetes, obesity and kidney diseases, chronic pain, and rehabilitation after cochlear implants; radiation therapy; internal medicine; and neurosurgery and neuroradiology. The company also provides services in the areas of oncology, and ENT, as well as acute outpatient services. As of January 01, 2021, it owned 35 clinics, 7 nursing care facilities, and 10 medical care centers with a total capacity of approximately 8,350 beds/ care places in 11 German federal states. The company is headquartered in Offenburg, Germany.",
    "website": "http://www.mediclin.de",
    "zipcode": "77652"
  },
  "MF6.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "MagForce AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MAGFORCE AG",
    "state": null,
    "summary": "MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that could be activated in an alternative magnetic field; NanoPlan, a therapy planning simulation software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany.",
    "website": "http://www.magforce.com",
    "zipcode": "12489"
  },
  "MF6.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "MagForce AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MAGFORCE AG",
    "state": null,
    "summary": "MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that could be activated in an alternative magnetic field; NanoPlan, a therapy planning simulation software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany.",
    "website": "http://www.magforce.com",
    "zipcode": "12489"
  },
  "MKGAF": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MKKGY": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MKLNF": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "M1 Kliniken AG",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "M1 KLINIKEN AG",
    "state": null,
    "summary": "M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select and M1 Aesthetics brands. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centres under the M1 Med Beauty, M1 Laser, and M1 Dental brand names. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.",
    "website": "http://www.m1-kliniken.de",
    "zipcode": "12557"
  },
  "MOR": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MorphoSys AG",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MOR.DE": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MORPHOSYS AG O.N.",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MOR.F": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MORPHOSYS AG O.N.",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MOR.VI": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "at_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MORPHOSYS AG",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MOR2.F": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MORPHOSYS AG SP.ADR(TEMP)",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MPSYF": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "MorphoSys AG",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MORPHOSYS",
    "state": null,
    "summary": "MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
    "website": "http://www.morphosys.com",
    "zipcode": "82152"
  },
  "MRCK.VI": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.DE": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA O.N.",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.F": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA O.N.",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.MI": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRKC.SG": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Merck KGaA Nam.-Akt.(Sp.ADRs) 1",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "NGRC": {
    "city": "Duesseldorf",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "National Graphite Corp.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NATIONAL GRAPHITE CORP",
    "state": null,
    "summary": "National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.",
    "website": null,
    "zipcode": "40237"
  },
  "NMI.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "Aladdin Healthcare Technologies SE",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALADDIN HLTHC.TECH. O.N.",
    "state": null,
    "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
    "website": "http://www.aladdinid.com",
    "zipcode": "10117"
  },
  "NMI.DU": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "DUS",
    "industry": "Health Information Services",
    "long_name": "Aladdin Healthcare Technologies SE",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALADDIN HLTHC.TECH. O.N.",
    "state": null,
    "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
    "website": "http://www.aladdinid.com",
    "zipcode": "10117"
  },
  "NMI.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Aladdin Healthcare Technologies SE",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALADDIN HLTHC.TECH. O.N.",
    "state": null,
    "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
    "website": "http://www.aladdinid.com",
    "zipcode": "10117"
  },
  "NN6.DE": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "NN6.F": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "NNGRF": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "NXU.DE": {
    "city": "Donaueschingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Health Information Services",
    "long_name": "Nexus AG",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NEXUS AG O.N.",
    "state": null,
    "summary": "Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a Web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany.",
    "website": "http://de-de.nexus-ag.de",
    "zipcode": "78166"
  },
  "NXU.F": {
    "city": "Donaueschingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Nexus AG",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NEXUS AG O.N.",
    "state": null,
    "summary": "Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a Web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany.",
    "website": "http://de-de.nexus-ag.de",
    "zipcode": "78166"
  },
  "PA8.DE": {
    "city": "Aachen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Paion AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PAION O.N",
    "state": null,
    "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
    "website": "http://www.paion.com",
    "zipcode": "52062"
  },
  "PA8.F": {
    "city": "Aachen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Paion AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PAION O.N",
    "state": null,
    "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
    "website": "http://www.paion.com",
    "zipcode": "52062"
  },
  "PHH2.F": {
    "city": "Heidenheim",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Paul Hartmann AG",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PAUL HARTMANN AG NA O.N.",
    "state": null,
    "summary": "Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. The company also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. In addition, it markets body care, dietary supplements, and herbal medicinal products; and distributes private-label products, such as cotton/cosmetic, medical, and baby and home care products. The company was founded in 1818 and is based in Heidenheim, Germany.",
    "website": "http://hartmann.info",
    "zipcode": "89522"
  },
  "PLHNF": {
    "city": "Heidenheim",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Paul Hartmann AG",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PAUL HARTMANN AG",
    "state": null,
    "summary": "Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. The company also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. In addition, it markets body care, dietary supplements, and herbal medicinal products; and distributes private-label products, such as cotton/cosmetic, medical, and baby and home care products. The company was founded in 1818 and is based in Heidenheim, Germany.",
    "website": "http://hartmann.info",
    "zipcode": "89522"
  },
  "PSG.DE": {
    "city": "GrÃ¤felfing",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "PharmaSGP Holding SE",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARMASGP HOLDING SE O.N.",
    "state": null,
    "summary": "PharmaSGP Holding SE manufactures non-chemical, over-the-counter drugs, and other healthcare products. The company's pharmaceutical products include RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, and Spain. PharmaSGP Holding SE was founded in 2012 and is based in GrÃ¤felfing, Germany.",
    "website": "http://pharmasgp.com",
    "zipcode": "82166"
  },
  "PSG.F": {
    "city": "GrÃ¤felfing",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "PharmaSGP Holding SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARMASGP HOLDING SE O.N.",
    "state": null,
    "summary": "PharmaSGP Holding SE manufactures non-chemical, over-the-counter drugs, and other healthcare products. The company's pharmaceutical products include RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, and Spain. PharmaSGP Holding SE was founded in 2012 and is based in GrÃ¤felfing, Germany.",
    "website": "http://pharmasgp.com",
    "zipcode": "82166"
  },
  "PUS.MU": {
    "city": "Feldkirchen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Medical Devices",
    "long_name": "PULSION Medical Systems SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PULSION ST O.N.",
    "state": null,
    "summary": "PULSION Medical Systems SE engages in the development and sale of monitoring systems and disposables for diagnosis and treatment of patients worldwide. The company offers its principal products in the fields of anesthesia, surgical and internal intensive care medicine, and cardiology, as well as ophthalmology and tumor therapy. PULSION Medical Systems SE was founded in 1990 and is headquartered in Feldkirchen, Germany.",
    "website": "http://www.pulsion.com",
    "zipcode": "85622"
  },
  "QBI.HM": {
    "city": "Mannheim",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "HAM",
    "industry": "Biotechnology",
    "long_name": "Q2M Managementberatung AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Q2M MGMT.BERAT.AG",
    "state": null,
    "summary": "Q2M Managementberatung AG provides provides management consultancy services. It offers succession planning, interim management, and operational implementation services. The company is based in Mannheim, Germany.",
    "website": "http://www.q2m-ag.com",
    "zipcode": "68199"
  },
  "RHK.DE": {
    "city": "Bad Neustadt an der Saale",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "RHÖN-KLINIKUM Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RHOEN-KLINIKUM O.N.",
    "state": null,
    "summary": "RHÃN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
    "website": "http://www.rhoen-klinikum-ag.com",
    "zipcode": "97616"
  },
  "RHK.F": {
    "city": "Bad Neustadt an der Saale",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "RHÖN-KLINIKUM Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RHOEN-KLINIKUM O.N.",
    "state": null,
    "summary": "RHÃN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
    "website": "http://www.rhoen-klinikum-ag.com",
    "zipcode": "97616"
  },
  "RHK.VI": {
    "city": "Bad Neustadt an der Saale",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Care Facilities",
    "long_name": "RHÖN-KLINIKUM Aktiengesellschaft",
    "market": "at_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RHOEN-KLINIKUM AG",
    "state": null,
    "summary": "RHÃN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
    "website": "http://www.rhoen-klinikum-ag.com",
    "zipcode": "97616"
  },
  "RHKU.F": {
    "city": "Bad Neustadt an der Saale",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "RHÖN-KLINIKUM Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RHOEN-KLINIK.UNSP.ADR 1/2",
    "state": null,
    "summary": "RHÃN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
    "website": "http://www.rhoen-klinikum-ag.com",
    "zipcode": "97616"
  },
  "SARTF": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "SBH.HM": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "HAM",
    "industry": "Biotechnology",
    "long_name": "Sangui Biotech International, Inc.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SANGUI BIOTECH INTL",
    "state": null,
    "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
    "website": "http://www.sanguibiotech.com",
    "zipcode": "20354"
  },
  "SBS.DE": {
    "city": "Birkenfeld",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Devices",
    "long_name": "Stratec SE",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STRATEC SE  NA O.N.",
    "state": null,
    "summary": "Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.",
    "website": "http://www.stratec.com",
    "zipcode": "75217"
  },
  "SBS.F": {
    "city": "Birkenfeld",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Stratec SE",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STRATEC SE  NA O.N.",
    "state": null,
    "summary": "Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.",
    "website": "http://www.stratec.com",
    "zipcode": "75217"
  },
  "SGBI": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Sangui Biotech International, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SANGUI BIOTECH INTERNATIONAL",
    "state": null,
    "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
    "website": "http://www.sanguibiotech.com",
    "zipcode": "20354"
  },
  "SHL.DE": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH.AG NA O.N.",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL.F": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH.AG NA O.N.",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL.VI": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTHINEERS AG",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL1.F": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH ADR/0,50",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SMMNY": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTHINEERS AG",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SRT.DE": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG O.N.",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "SRT.F": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG O.N.",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "SRT3.DE": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG VZO O.N.",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "SRT3.F": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG VZO O.N.",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "SRT3.VI": {
    "city": "GÃ¶ttingen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sartorius Aktiengesellschaft",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SARTORIUS AG VZO",
    "state": null,
    "summary": "Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in GÃ¶ttingen, Germany.",
    "website": "http://www.sartorius.com",
    "zipcode": "37079"
  },
  "STSEY": {
    "city": "Birkenfeld",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Stratec SE",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STRATEC SE UNSPN ADS EACH REP 0",
    "state": null,
    "summary": "Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.",
    "website": "http://www.stratec.com",
    "zipcode": "75217"
  },
  "SYAB.F": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "SYNLAB AG",
    "market": "dr_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "SYNLAB AG  INH O.N.",
    "state": null,
    "summary": "SYNLAB AG provides clinical laboratory and medical diagnostic services for practicing doctors, clinics, patients, and the pharmaceutical industry primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 450 laboratories and 1,600 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.",
    "website": "http://www.synlab.com",
    "zipcode": "80809"
  },
  "SYAB.VI": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "SYNLAB AG",
    "market": "at_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "SYNLAB AG",
    "state": null,
    "summary": "SYNLAB AG provides clinical laboratory and medical diagnostic services for practicing doctors, clinics, patients, and the pharmaceutical industry primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 450 laboratories and 1,600 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.",
    "website": "http://www.synlab.com",
    "zipcode": "80809"
  },
  "V3V.DE": {
    "city": "Leipzig",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Medical Care Facilities",
    "long_name": "VITA 34 AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VITA 34 AG NA O.N.",
    "state": null,
    "summary": "VITA 34 AG engages in the collection, preparation, cryopreservation, and storage of stem cells from umbilical cord blood and tissue in Europe. The company offers Sibling Initiative that offers free storage of stem cells collected from the umbilical cord blood of a child whose brother or sister is seriously ill and needs the stem cells from the newborn sibling for treatment purposes; VitaPlusDonation that stores stem cells for personal therapeutic stem cell application; and VitaMine&Yours, which combines the storage of umbilical cord blood for personal provision with the possibility of a donation. It also provides Prevention screenings, which enable the detection of genetically related health risks and predispositions; and mobile stem cell team that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is based in Leipzig, Germany.",
    "website": "http://www.vita34.de",
    "zipcode": "04103"
  },
  "V3V.F": {
    "city": "Leipzig",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "VITA 34 AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VITA 34 AG NA O.N.",
    "state": null,
    "summary": "VITA 34 AG engages in the collection, preparation, cryopreservation, and storage of stem cells from umbilical cord blood and tissue in Europe. The company offers Sibling Initiative that offers free storage of stem cells collected from the umbilical cord blood of a child whose brother or sister is seriously ill and needs the stem cells from the newborn sibling for treatment purposes; VitaPlusDonation that stores stem cells for personal therapeutic stem cell application; and VitaMine&Yours, which combines the storage of umbilical cord blood for personal provision with the possibility of a donation. It also provides Prevention screenings, which enable the detection of genetically related health risks and predispositions; and mobile stem cell team that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is based in Leipzig, Germany.",
    "website": "http://www.vita34.de",
    "zipcode": "04103"
  },
  "VSC.DE": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "4SC AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "4SC AG",
    "state": null,
    "summary": "4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",
    "website": "http://www.4sc.de",
    "zipcode": "82152"
  },
  "VSC.F": {
    "city": "Planegg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "4SC AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "4SC AG",
    "state": null,
    "summary": "4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",
    "website": "http://www.4sc.de",
    "zipcode": "82152"
  },
  "VVY.AS": {
    "city": "Halle",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "AMS",
    "industry": "Biotechnology",
    "long_name": "Vivoryon Therapeutics N.V.",
    "market": "nl_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VIVORYON",
    "state": null,
    "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
    "website": "http://www.vivoryon.com",
    "zipcode": "06120"
  }
}
